Table 2 Validation studies for association of MICA with the risk of HCC development among chronic hepatitis patients
From: Main insights of genome wide association studies into HCV-related HCC
Study/year | Ethnicity | Cases/controls | P value | OR (95%CI) |
|---|---|---|---|---|
Kumar 2012 [10] | Japanese | 407 HCC cases/699 CHB subjects and 5657 non-HBV controls | 0.029 | 1.19 ( 1.02–1.4) |
Lo 2013 [11] | Japanese | 1394 HCV-HCC/1629 LC-CHC | 0.2 | – |
Lange 2013 [12] | European | 68 HCV-related HCC patients/1860 HCV patients | 0.03 | 0.58 (0.35–0.95) |
Chang 016 [13] | Chinese | 120 HCC/124 healthy controls | 0.02 | 1.57(1.07–2.31) |
Burza 2016 [14] | European | 192 LC-HCC/199 LC | 0.34 | – |
Huang 2017 [15] | Taiwanese | Cohort of 705 patients receiving INF based antiviral therapy. 58 develop HCC/647 did not develop HCC | 0.002 | 4·37(1.52–12.07) |
Mohamed 2017 [16] | Egyptian | 47HCV-HCC/47HCV-LC and 47 healthy controls | HCC vs. healthy 0.01 | HCC vs. healthy 2.1 (1.17–3.78) |
Hai 2017 [17] | Japanese | 142 HCV-HCC/575 HCV non-HCC patients | 0.0002 | 4.47 (2.04–9.80) |
Augello 2018 [18] | Italian | 154 HCV-HCC/93 HCV-LC and 244 healthy controls | HCC VS controls = 0.03 HCC VS LC = 0.04 | HCC VS controls 0.599 (0.371–0.968) HCC VS LC 0.522 (0.276–0.989) |